Shares of Cellectis SA (NASDAQ:CLLS) shot up 2.8% during mid-day trading on Wednesday . The stock traded as high as $27.00 and last traded at $26.12, with a volume of 92,832 shares traded. The stock had previously closed at $25.41.

Several research firms recently issued reports on CLLS. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Cellectis SA in a report on Tuesday, May 31st. Piper Jaffray Cos. restated a “buy” rating on shares of Cellectis SA in a research note on Sunday, May 8th. Zacks Investment Research lowered Cellectis SA from a “hold” rating to a “sell” rating in a research note on Thursday, May 12th. Finally, Ladenburg Thalmann initiated coverage on Cellectis SA in a research note on Tuesday, April 5th. They issued a “buy” rating and a $45.00 price objective on the stock. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $44.67.

The stock’s 50 day moving average is $28.54 and its 200-day moving average is $26.84. The firm’s market cap is $900.43 million.

Cellectis SA (NASDAQ:CLLS) last posted its quarterly earnings results on Thursday, May 12th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.18. Equities research analysts forecast that Cellectis SA will post ($2.07) EPS for the current fiscal year.

A hedge fund recently raised its stake in Cellectis SA stock. Tekla Capital Management LLC increased its position in Cellectis SA (NASDAQ:CLLS) by 30.9% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 207,250 shares of the company’s stock after buying an additional 48,868 shares during the period. Tekla Capital Management LLC owned about 0.59% of Cellectis SA worth $6,431,000 at the end of the most recent quarter.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.